Clinical Trial Update: Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Namodenoson is being studied in a Phase 2 trial for Nonalcoholic Steatohepatitis (NASH), and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Namodenoson (Namodenoson)

Snippet

Sponsor: Can-Fite BioPharma | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: RECRUITING